35 min
The Promise of Anti-Amyloid Therapies: Roundtable Excerpt 2 Bob's Last Marathon
-
- Mental Health
The somewhat complex logistics for both the clinic and the patient in administering Leqembi (lecanemab), the first fully FDA-approved drug for Alzheimer’s disease in over 20 years, are summarized in this second of two excerpts from a recent roundtable. Dr. Steven E. Arnold and Dr. David A. Wolk highlight some of the risk factors, including genetic risk factors. They postulate that Alzheimer’s disease may be more than amyloid and perhaps more than amyloid and tau, and ponder a future of combination therapy and precision medicine, where therapies are targeted toward individual patients.
The somewhat complex logistics for both the clinic and the patient in administering Leqembi (lecanemab), the first fully FDA-approved drug for Alzheimer’s disease in over 20 years, are summarized in this second of two excerpts from a recent roundtable. Dr. Steven E. Arnold and Dr. David A. Wolk highlight some of the risk factors, including genetic risk factors. They postulate that Alzheimer’s disease may be more than amyloid and perhaps more than amyloid and tau, and ponder a future of combination therapy and precision medicine, where therapies are targeted toward individual patients.
35 min